Patents Examined by Cecilia J. Tsang
  • Poly(lactide-co-glycolide) based sustained release microcapsules comprising a polypeptide and a sugar
    Patent number: 8293871
    Abstract: This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.
    Type: Grant
    Filed: April 15, 2005
    Date of Patent: October 23, 2012
    Assignees: Alkernnes Pharma Ireland Limited, Amylin Pharmaceuticals, Inc.
    Inventors: Steven G. Wright, Troy Christensen, Thean Yeoh, Michael E. Rickey, Joyce M. Hotz, Rajesh Kumar, Henry R. Costantino, Christine Smith, David M. Lokensgard, Mark Fineman, John Ong
  • Targeting and therapeutic compounds and gas-filled microvesicles comprising said compounds
    Patent number: 8293214
    Abstract: New targeting or therapeutic compounds which can be incorporated into a composition of gas-filled microvesicles. The invention further relates to gas-filled microvesicles for diagnostic and/or therapeutic use comprising said compounds and to their method of use. The new compounds are compounds of formula M-S-T, wherein: M represents a component capable of associating with an envelope of a gas-filled microvesicle; T represents a component comprising a targeting ligand or a therapeutic agent; and S represents a component comprising at least two bissulfone groups.
    Type: Grant
    Filed: December 19, 2007
    Date of Patent: October 23, 2012
    Assignee: Bracco Suisse S.A.
    Inventors: Rolf E. Swenson, Philippe Bussat, Bernard Lamy, Sibylle Pochon, Kondareddiar Ramalingam
  • HCV protease inhibitors and uses thereof
    Patent number: 8293705
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: July 2, 2009
    Date of Patent: October 23, 2012
    Assignee: Avila Therapeutics, Inc.
    Inventors: Deqiang Niu, Russell C. Petter, Juswinder Singh, Arthur F. Kluge, Lixin Qiao
  • Antiviral compounds
    Patent number: 8283442
    Abstract: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: October 9, 2012
    Assignee: Gilead Sciences, Inc.
    Inventors: Aesop Cho, Michael O'Neil Hanrahan Clarke, Choung U. Kim, John O. Link, Hyung-jung Pyun, Xiaoning C. Sheng, Qiaoyin Wu
  • Bridged carbocyclic oxime hepatitis C virus serine protease inhibitors
    Patent number: 8283309
    Abstract: The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. More specifically, the invention relates to oxime compounds containing a carbocyclic P2 unit, and the oxime is tethered to one of the carboxylic acid on P2. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: October 9, 2012
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Dong Liu, Yat Sun Or, Zhe Wang
  • Hepatitis C virus inhibitors
    Patent number: 8283310
    Abstract: Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: December 10, 2009
    Date of Patent: October 9, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alan Xiangdong Wang, Paul Michael Scola
  • Virus scaffold for self-assembled, flexible and light lithium battery
    Patent number: 8283325
    Abstract: A variety of compositions that include a metal oxide, films and batteries comprising one or more of the compositions, and methods of making the same.
    Type: Grant
    Filed: October 19, 2005
    Date of Patent: October 9, 2012
    Assignee: Massachusetts Institute of Technology
    Inventors: Ki Tae Nam, Chung-Yi Chiang, Angela M. Belcher
  • GLP-1 analog fusion proteins
    Patent number: 8273854
    Abstract: The invention provides specific GLP-1 analogs fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life, decreased immunogenicity, and reduce effector activity. The fusion proteins are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.
    Type: Grant
    Filed: October 31, 2008
    Date of Patent: September 25, 2012
    Assignee: Eli Lilly and Company
    Inventors: Wolfgang Glaesner, Rohn Lee Millican, Jr., Andrew Mark Vick
  • Triazole-containing macrocyclic HCV serine protease inhibitors
    Patent number: 8273709
    Abstract: The present invention discloses compounds of formula I, II and III or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: December 12, 2008
    Date of Patent: September 25, 2012
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yonghua Gai, Yat Sun Or, Zhe Wang
  • Macrocylic oximyl hepatitis C protease inhibitors
    Patent number: 8268776
    Abstract: The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: January 18, 2008
    Date of Patent: September 18, 2012
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Ying Sun, Deqiang Niu, Guoyou Xu, Yat Sun Or, Zhe Wang
  • Oximyl macrocyclic derivatives
    Patent number: 8268777
    Abstract: The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
    Type: Grant
    Filed: December 3, 2008
    Date of Patent: September 18, 2012
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Ying Sun, Deqiang Niu, Guoyou Xu, Yat Sun Or, Zhe Wang
  • PAR-2 antagonists
    Patent number: 8268789
    Abstract: Compounds represented by the general formula (1) or salts thereof or solvates of both; PAR-2 antagonists containing the compounds; and preventive or therapeutic agents for PAR-2 related diseases containing the antagonists as the active ingredient: (1) wherein R1 is hydrogen, halogeno, or a group represented by the general formula (2): (wherein R11 is straight-chain or branched C1-6 alkylene or the like; and R12 and R13 together with the nitrogen atom adjacent to them form a 5- to 7-membered ring); R2 is straight-chain or branched C1-6 alkyl or the like; R3 and R4 are each independently hydrogen, one to three halogen atoms, or the like; and A1-A2-A3 is a tripeptide residue composed of ?-amino acids each independently selected from the group consisting of glycine, alanine, cyclohexylalanine, and so on.
    Type: Grant
    Filed: September 30, 2005
    Date of Patent: September 18, 2012
    Assignee: Kowa Company, Ltd.
    Inventors: Mototsugu Kabeya, Kyoko Yasuoka, Toru Kanke, Hiroyuki Ishiwata, Junya Tagashira
  • C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors
    Patent number: 8263549
    Abstract: The present invention relates to compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: September 11, 2012
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Joel D. Moore, Yat Sun Or, Zhe Wang
  • HPV 16 peptide vaccine for head and neck cancer
    Patent number: 8263560
    Abstract: The present invention relates to Trojan antigens, and immunogenic compositions comprising the Trojan antigens. The present invention also relates to methods of generating an immune response in a subject using the Trojan antigens or immunogenic compositions. The present invention further relates to methods of treating squamous cell carcinoma of the head and neck (SCCHN) using the Trojan antigens and immunogenic compositions of the present invention.
    Type: Grant
    Filed: August 13, 2007
    Date of Patent: September 11, 2012
    Assignees: University of Maryland Baltimore, Mayo Foundation for Medical Education and Research
    Inventors: Scott E. Strome, Esteban Celis
  • Cell penetrating peptides for intracellular delivery of molecules
    Patent number: 8242081
    Abstract: The present invention concerns cell-penetrating peptides which comprise an amino acid sequence consisting of GLX9RALX9RX1LX2RSLX9X3X4X5X6X7X8 (SEQ ID No: 1), wherein X1 is A, L or G, X2 is W or none, X3 is R or K, X4 is K, L or S, X5 is L or K, X6 is R or W, X7 is K or S, and X8 is A, V or Q, and X9 is W, F or Y. These CPPs can be used as vectors for delivering nucleic acids and/or proteins and/or peptides to cells, in vitro or in vivo.
    Type: Grant
    Filed: December 5, 2006
    Date of Patent: August 14, 2012
    Assignees: Centre National de la Recherche Scientifique, Affymetrix, Inc.
    Inventors: Gilles Divita, Frédéric Heitz, May Catherine Morris, Gudrun Aldrian-Herrada
  • Biosensor
    Patent number: 8242077
    Abstract: The invention provides a product comprising: a membrane-spanning protein; a lipid membrane formed from amphiphilic molecules and membrane-spanning protein molecules; and a substrate, wherein the membrane protein is directly coupled to the substrate. The invention also provides a method for producing such a product which i) comprises treating a substrate with a hydrophilic coating agent; ii) providing at least one membrane-spanning protein; iii) bringing the protein into contact with the treated substrate under conditions for the coupling of the protein directly to the treated substrate; and iv) adding amphiphilic molecules to the protein-coupled substrate to form a lipid membrane. The product is useful for biosensors, protein arrays and the like.
    Type: Grant
    Filed: September 16, 2008
    Date of Patent: August 14, 2012
    Assignee: Newcastle University Ventures Limited
    Inventors: Jeremy Hugh Lakey, Horst Vogel
  • Anti-viral compounds
    Patent number: 8232246
    Abstract: Compounds capable of inhibiting replication of the hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: July 31, 2012
    Assignee: Abbott Laboratories
    Inventors: Keith F. McDaniel, Dale J. Kempf
  • Compounds for delivery of therapeutic and imaging moieties to nerve cells
    Patent number: 8232251
    Abstract: The invention features compounds of the general formula: B-L-M where B is a binding agent capable of selectively binding to a nerve cell surface receptor and mediating absorption of the compound by the nerve cell; M is a moiety which performs a useful non-cytotoxic function when absorbed by a nerve cell, and can be a therapeutic moiety or an imaging moiety; and L is a linker coupling B to M. The invention also features methods of use of the compounds in, for example, treating conditions such as viral infections and pain, as well as in labeling nerve cells.
    Type: Grant
    Filed: November 25, 2008
    Date of Patent: July 31, 2012
    Assignee: Manzanita Pharmaceuticals, Inc.
    Inventors: G. Craig Hill, Stephen B. Kahl, Robert R. Webb, Constance A. McKee
  • Fluorinated GHRH antagonists
    Patent number: 8227405
    Abstract: Novel fluorinated synthetic analogs of hGH-RH(1-30)NH2 that inhibit the release of growth hormone from the pituitary in mammals as well as inhibit the proliferation of human cancers through a direct effect on the cancer cells, and to therapeutic compositions containing these novel peptides and their use.
    Type: Grant
    Filed: September 17, 2009
    Date of Patent: July 24, 2012
    Assignees: University of Miami, The United States of America as represented by the Department of Veterans Affairs
    Inventors: Andrew Schally, Jozsef Varga, Marta Zarandi, Ren Zhi Cai
  • A-? immunogenic peptide carrier conjugates and methods of producing same
    Patent number: 8227403
    Abstract: The present invention is directed to methods of producing conjugates of A? peptide immunogens with protein/polypeptide carrier molecules, which are useful as immunogens, wherein peptide immunogens are conjugated to protein carriers via activated functional groups on amino acid residues of the carrier or of the optionally attached linker molecule, and wherein any unconjugated reactive functional groups on amino acid residues are inactivated via capping, thus retaining the immunological functionality of the carrier molecule, but reducing the propensity for undesirable reactions that could render the conjugate less safe or effective. Furthermore, the invention also relates to such immunogenic products and immunogenic compositions containing such immunogenic products made by such methods.
    Type: Grant
    Filed: December 17, 2004
    Date of Patent: July 24, 2012
    Assignees: Wyeth LLC, Janssen Alzheimer Immunotherapy
    Inventors: Rasappa G. Arumugham, A. Krishna Prasad, Michael Hagen